| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/meet-2-formerly-down-and-out-stocks-are-outperforming-sp-500-year-are-they-still-buy","as_of":"2026-04-09T12:08:05.625638+00:00","canonical_url":"https://www.fool.com/investing/2026/04/09/meet-the-2-formerly-down-and-out-stocks-that-are-o/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/meet-2-formerly-down-and-out-stocks-are-outperforming-sp-500-year-are-they-still-buy","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_3c5c98b25501dada","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/09/meet-the-2-formerly-down-and-out-stocks-that-are-o/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T00:23:20.955979+00:00","extraction_method":"heuristic","fetched_description":"Key PointsIn an uncertain market, investors have rushed to get in on these players seen as \"safer\" investments.","fetched_title":"Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy? | Nasdaq","final_url":"https://www.nasdaq.com/articles/meet-2-formerly-down-and-out-stocks-are-outperforming-sp-500-year-are-they-still-buy","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/meet-2-formerly-down-and-out-stocks-are-outperforming-sp-500-year-are-they-still-buy","source_event_id":"evt_d05e6c48bdd1","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"5b911bdbe3f652b2","kind":"unusual_volume","published_at":"2026-04-09T11:30:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":["April 09, 2026"],"entities":[{"asset_class":"equity","name":"Moderna","relevance":"high","symbol":"MRNA","type":"company"},{"asset_class":"equity","name":"Target","relevance":"high","symbol":"TGT","type":"company"},{"asset_class":"index","name":"S&P 500","relevance":"medium","symbol":"","type":"index"},{"asset_class":"equity","name":"Walmart","relevance":"medium","symbol":"WMT","type":"company"},{"asset_class":"equity","name":"Nvidia","relevance":"low","symbol":"NVDA","type":"company"},{"asset_class":"equity","name":"Alphabet","relevance":"low","symbol":"GOOG","type":"company"},{"asset_class":"equity","name":"Intel","relevance":"low","symbol":"INTC","type":"company"}],"event_type":"other","information_gaps":["This signal type requests unusual volume delta (volume ratio vs average), but the provided text contains no volume metrics, no baseline volume, and no volume ratio for any ticker.","The article does not explicitly state whether any volume surge is confirmed by news or is unexplained; it only discusses price performance and narrative catalysts.","The headline mentions \u201c2 Formerly Down-and-Out Stocks,\u201d but the text does not provide any explicit volume confirmation tied to the headline."],"key_facts":["The article states that investors became more cautious in recent weeks due to headwinds including \u201cturmoil in Iran\u201d and \u201ceconomic growth in the U.S.\u201d","The article claims investors shifted from AI stocks to healthcare and retail stocks viewed as safer because medications and essential products are needed regardless of conditions.","The article says Moderna (NASDAQ: MRNA) has \u201csoar[ed] nearly 70%\u201d since the start of the year.","The article says Moderna dropped \u201c90% through the end of 2025\u201d after its vaccine peak.","The article states Moderna has a plan involving cost cuts and focus on seasonal vaccines, oncology, and rare diseases.","The article says Moderna sells two coronavirus vaccines and an RSV vaccine, and that regulators are reviewing its flu candidate \u201cright now.\u201d","The article says Moderna recently reaffirmed its forecast for \u201cas much as 10% revenue growth this year.\u201d","The article says Target (NYSE: TGT) has advanced \u201cmore than 20% from the beginning of the year.\u201d","The article describes Target\u2019s turnaround plan led by CEO Michael Fiddelke, including improving displays/floor plans, refreshing assortment, and employee training.","The article states Target\u2019s plan includes a \u201c$2 billion investment this year alone\u201d and is multi-year.","The article states Target trades at \u201c14x forward earnings estimates,\u201d lower than retail peers such as Walmart and Costco (which are described as trading at more than 40x)."],"numeric_claims":[{"label":"Moderna performance since start of year","value":"nearly 70%"},{"label":"Moderna decline from peak","value":"90% through end of 2025"},{"label":"Moderna forecast revenue growth","value":"as much as 10% this year"},{"label":"Target performance since beginning of year","value":"more than 20%"},{"label":"Target investment this year","value":"$2 billion"},{"label":"Target forward earnings multiple","value":"14x"},{"label":"Walmart/Costco forward earnings multiple (described)","value":"more than 40x"}],"primary_claim":"Since the start of the year, Moderna (MRNA) and Target (TGT) are outperforming the S&P 500, and the article frames them as potentially still attractive buys based on their respective recovery/turnaround plans.","relevance_score":0.25,"sentiment":"mixed","source_quality":"high","summary":"The article argues that investors have rotated from tech/AI into \u201csafer\u201d healthcare and retail stocks amid macro uncertainty, highlighting Moderna and Target as outperformers this year. It attributes the outperformance to Moderna\u2019s recovery narrative and Target\u2019s turnaround plan and investment.","topics":["market rotation","healthcare stocks","retail stocks","biotech recovery","company turnaround","investor sentiment","macro uncertainty"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsIn an uncertain market, investors have rushed to get in on these players seen as \u201csafer\u201d investments.","tickers":[],"title":"Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?","url":"https://www.fool.com/investing/2026/04/09/meet-the-2-formerly-down-and-out-stocks-that-are-o/"}... |